中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.038 seconds)

    CHONDROGENIC HUMAN MESENCHYMAL STEM CELL (MSC) SHEETS
    2.
    发明公开
    CHONDROGENIC HUMAN MESENCHYMAL STEM CELL (MSC) SHEETS 审中-公开

    公开(公告)号：US20240052313A1

    公开(公告)日：2024-02-15

    申请号：US17766292

    申请日：2020-10-07

    Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION

    Inventor： Teruo Okano ,  Kyungsook Kim ,  Hallie Thorp ,  David W. Grainger ,  Travis Maak

    IPC: C12N5/077 ,  A61P19/02

    CPC classification number: C12N5/0655 ,  A61P19/02 ,  C12N2506/1353 ,  C12N2533/54 ,  C12N2501/155 ,  C12N2501/60 ,  C12N2501/998 ,  C12N2501/15

    Abstract: The disclosure relates to a chondrogenic cell sheet comprising at least two layers of confluent chondrogenically differentiated cells, wherein the cell sheet is prepared from mesenchymal stem cells (MSCs), and wherein the chondrogenically differentiated cells on the basal side of the cell sheet express adhesion molecules. The disclosure also relates to a method of preparing a chondrogenic cell sheet comprising: a) culturing MSCs on temperature responsive cultureware until confluent to form a cell sheet; b) detaching the cell sheet by temperature reduction and allowing the cell sheet to contract, forming a contracted cell sheet; c) contacting the contracted cell sheet with a culture surface; and d) treating the contracted cell sheet on the culture surface with chondrogenic medium and culturing to form a chondrogenic cell sheet. Methods of using the chondrogenic cell sheets to repair cartilage tissue or treat joint disease are also disclosed.

    TISSUE FIXATION
    5.
    发明申请
    TISSUE FIXATION 审中-公开
    组织固定

    公开(公告)号：US20150173764A1

    公开(公告)日：2015-06-25

    申请号：US14576814

    申请日：2014-12-19

    Applicant: University of Utah Research Foundation

    Inventor： Erik N. Kubiak ,  Emmon J. Chen ,  David W. Grainger

    IPC: A61B17/11

    CPC classification number: A61B17/1146 ,  A61B2017/00004 ,  A61B2017/00526 ,  A61F2/08 ,  A61F2/0811

    Abstract: Methods and systems are provided for tissue stabilization. Some aspects include a carrier member having a length, width, and thickness, wherein the length and width are each at least two times greater than the thickness; attachment members extending from the carrier member and that engage connective tissue; and stabilizing members, each of which can couple a respective attachment member to the carrier member and is substantially positionally fixed relative to the carrier member.

    Abstract translation: 为组织稳定提供了方法和系统。 一些方面包括具有长度，宽度和厚度的载体构件，其中长度和宽度各自为厚度的至少两倍; 附着构件从承载构件延伸并接合结缔组织; 以及稳定构件，每个构件可将相应的附接构件联接到承载构件上，并且相对于承载构件基本上位置固定。

    Drug Release from a Polymer-Controlled Local Antibiotic Delivery System Using a Degradable Bone Graft
    6.
    发明申请
    Drug Release from a Polymer-Controlled Local Antibiotic Delivery System Using a Degradable Bone Graft 审中-公开
    使用可降解骨移植的聚合物控制的局部抗生素递送系统的药物释放

    公开(公告)号：US20130209522A1

    公开(公告)日：2013-08-15

    申请号：US13759904

    申请日：2013-02-05

    Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION

    Inventor： Amanda Elaine Brooks ,  Benjamin Delbert Brooks ,  David W. Grainger

    IPC: A61K47/46 ,  A61K31/431 ,  A61K38/14 ,  A61K31/496 ,  A61K31/7036 ,  A61K47/34

    CPC classification number: A61K47/46 ,  A61K31/351 ,  A61K31/431 ,  A61K31/496 ,  A61K31/7036 ,  A61K35/32 ,  A61K38/14 ,  A61K47/34 ,  A61L27/3608 ,  A61L27/46 ,  A61L27/54 ,  A61L27/56 ,  A61L2300/406 ,  A61L2400/08 ,  A61L2430/02 ,  C08L67/04 ,  C08L71/02

    Abstract: In some embodiments, the invention provides an implant comprising a uniform mixture of degradable polymer, bone, and a drug. In some embodiments, the drug comprises an antibiotic. In some embodiments, diffusion of the drug from the implant at a therapeutic level is maintained for an amount of time longer than an amount of time that a pathogen is senescent. In some embodiments, diffusion of the drug from the implant at a therapeutic level is maintained for at least eight weeks, or at least ten weeks, or at least twelve weeks post-implantation. In some embodiments, the therapeutic level is maintained at an implantation site of the implant.In some embodiments, the implant is a solid, a paste, or a liquid. In some embodiments, the solid implant is carved or molded for insertion into a site of implantation in a vertebrate host prior to implantation. In some embodiments, the paste implant hardens following implantation. In some embodiments, the liquid implant is used to coat a prosthesis (e.g., a prosthesis made of a metal, a ceramic, a porcelain, or a combination of two or more of the foregoing).

    Abstract translation: 在一些实施方案中，本发明提供了包含可降解聚合物，骨和药物的均匀混合物的植入物。 在一些实施方案中，药物包含抗生素。 在一些实施方案中，将药物从治疗水平的植入物扩散的时间长于病原体衰老的时间长度。 在一些实施方案中，药物从治疗水平的植入物的扩散在植入后保持至少八周，或至少十周，或至少十二周。 在一些实施例中，治疗水平保持在植入物的植入部位。 在一些实施例中，植入物是固体，糊剂或液体。 在一些实施例中，在植入之前，将固体植入物雕刻或模制成用于插入植入脊椎动物宿主的部位。 在一些实施例中，膏体植入物在植入后硬化。 在一些实施例中，液体植入物用于涂覆假体（例如，由金属，陶瓷，瓷器或前述的两个或多个的组合制成的假体）。

Patent Agency Ranking